NCT03654313View on ClinicalTrials.gov

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

July 21, 2020

Study Completion Date

July 21, 2020

Conditions
AtherosclerosisCardiovascular Disease
Interventions
BIOLOGICAL

MEDI6570

MEDI6570

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

Part B Placebo

Placebo

Trial Locations (9)

27265

Research Site, High Point

32127

Research Site, Port Orange

32216

Research Site, Jacksonville

33143

Research Site, Miami

36207

Research Site, Anniston

37920

Research Site, Knoxville

45227

Research Site, Cincinnati

78229

Research Site, San Antonio

96814

Research Site, Honolulu

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter